Collaborating for Better Care: Focus on AMD -

Thank you for attending. The posttest will not be available immediately.

It will be accessible once the link has been emailed to you, which will be within 48 hours of the conclusion of the symposium.

Note for ODs: COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual activity until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

Scroll back to top

Details

Overview
This symposium will highlight strategies for identifying patients who may benefit from the latest advances in age-related macular degeneration therapies and the potential advantages that longer duration therapies may offer. Drs. Dunbar, Goldberg, and Steen will also discuss potential strategies to overcome barriers to adherence.

Note About Obtaining Credit: You must remain logged in to the virtual course until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

The posttest will not be available immediately. It will be accessible once the link has been emailed to you, which will be within 48 hours of the conclusion of the symposium.
To receive credit, you must complete the posttest and evaluation and proceed to the claim credit page. Only attendees are eligible for credit.

This activity is supported by an unrestricted educational grant from Genentech, a member of the Roche Group.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Review advances in current treatments for diabetic eye disease and nAMD
- Identify patients who may benefit from advances in the treatment paradigm for retinal vascular diseases
- Formulate strategies to identify and resolve barriers to optimal treatment outcomes for patients with nAMD
- Summarize therapies for retinal vascular diseases that are in clinical development
Accreditation
Evolve Medical Education, LLC is a COPE-accredited administrator.
This activity, COPE Activity Number 126163, is accredited by COPE for continuing education for optometrists. This course is approved for 1 hour of CE.
Course #: 84733-TD
Activity #: 126163
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Bay Area Retina Associates
Volunteer Faculty
California Pacific Medical Center
Walnut Creek, CA

Mark T. Dunbar, OD, FAAO
Director of Optometry
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL

Jessica Steen, OD, FAAO
Associate Professor
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, Coherus Biosciences, EyePoint Pharmaceuticals, Genentech/Roche, Outlook, and Regeneron. Grant/Research Support: Affamed, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Genentech/Roche, Janssen, Neurotech, and Novo Nordisk. Speaker's Bureau: Apellis Pharmaceuticals, Biogen, and Genentech/Roche.
Mark T. Dunbar, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan, Carl Zeiss Meditec, Genentech, Reed Exhibitions, Regeneron, and Tarsus Pharmaceuticals. Consultant: Allergan, Avellino, Carl Zeiss Meditec, Genentech, Iveric Bio, Orasis Pharmaceuticals, Regeneron, and Visus. Speaker's Bureau: Allergan, Carl Zeiss Meditec, and Regeneron.
Jessica Steen, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch + Lomb, Ocuphire Pharma, OcuTerra, Peripherex, Santen, and Théa Pharma. Shareholder: Clearside Biomedical. Speaker's Bureau: Bausch + Lomb, Carl Zeiss Meditec, Oyster Point Pharma, and Théa Pharma.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Note About Obtaining Credit: You must remain logged in to the virtual course until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

The posttest will not be available immediately. It will be accessible once the link has been emailed to you, which will be within 48 hours of the conclusion of the symposium.
To receive credit, you must complete the posttest and evaluation and proceed to the claim credit page. Only attendees are eligible for credit.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 07/07/2023

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Title

Share on ReachMD